MNTN expects Q4 revenue of $75M-$78M as new CEO targets go-to-market reset

Seeking Alpha · November 5, 2026, 16:25 UTC

Topics: CEO transition go-to-market strategy revenue guidance

Read the full article at Seeking Alpha

Part of the story Travere Therapeutics Projects $3 Billion in FILSPARI Sales by 2033 Amid Patent Extensions (2 articles)

More World news

CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC
AiPrise Launches Token Sharing Infrastructure to Streamline Compliance Verification PR Newswire · November 12, 2026, 19:39 UTC
Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff Seeking Alpha · November 12, 2026, 19:32 UTC
Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan PR Newswire · November 12, 2026, 19:28 UTC
Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026 Motley Fool · November 12, 2026, 19:25 UTC
MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion Motley Fool · November 12, 2026, 19:25 UTC
Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA Motley Fool · November 12, 2026, 19:25 UTC